35 results about "Insulin treatments" patented technology

The present invention relates to a composition for the prevention or treatment of diabetes comprising a long-acting insulin conjugate and a long-acting insulinotropic peptide conjugate, and a therapeutic method for the treatment of diabetes, and more particularly, concurrent administration of the long-acting insulin conjugate and the long-acting insulinotropic peptide conjugate inhibits weight gain caused by insulin treatment, and vomiting and nausea caused by insulinotropic peptide treatment, and reduces the required dose of insulin, thereby remarkably improving drug compliance. Moreover, each of the long-acting insulin conjugate and the long-acting insulinotropic peptide conjugate of the present invention is prepared by linking insulin or insulinotropic peptide with an immunoglobulin Fc region via a non-peptidyl linker, thereby showing improved in-vivo duration of efficacy and stability.

Methods for treating impaired glucose tolerance and early and late stage diabetes in mammals, for prophylactically sparing β-cell function, aiding in preventing β-cell death, preventing the onset of overt diabetes in a mammal with type 2 diabetes, treating the current level of glycemic control dysfunction of a mammal with impaired glucose tolerance or diabetes, comprising orally administering insulin and a delivery agent that facilitates insulin absorption from the gastrointestinal tract at the time of or shortly before mealtime, e.g., within about 10 minutes prior to ingestion of a meal, on a chronic basis. The methods also comprise, in addition to administering a rapid-acting insulin to provide a first insulin peak, administering a slow acting insulin to provide a second insulin peak occurring at a later time but of a longer duration. These methods achieve improved glycemic control without the risks of hypoglycemia, hyperinsulinemia and weight gain and the need for frequent blood glucose monitoring that are normally associated with insulin therapy.

The invention provides a portable multifunctional intelligent insulin pump which has high degree of intensification and is based on the modern electronic technology, and a control module thereof, and the intelligent insulin pump is composed of an intelligent insulin pump body, a blood glucose detection sensor which is directly connected therewith and an infusion actuator. The change of the blood glucose is tracked by dynamic monitoring of the blood glucose level of a user, thus infusing the insulin for the treatment of diabetes. The insulin pump body is connected with a mobile phone by a communication protocol, and the user can control the infusion amount by the mobile phone. The errors of the monitoring of the blood glucose are calculated according to the characteristics of the self blood glucose and the basic amount of the normal blood glucose of the user, thus establishing the control model of the infusion pump. When the blood glucose content exceeds the allowable range, the controller emits a command, a drive mechanism allows the insulin in a liquid storage tank to pass a pipeline, and the insulin is infused to the body of the user by utilizing the infusion actuator. The invention is the complete and integrated novel insulin treatment instrument which has the effects of waterproof, corrosion resistance, vibration resistance and low power consumption and can not affect the normal life and be worked basically and normally.

A method of treating a patient in need of insulin treatment, including the steps of introducing into the lower respiratory tract of the patient an effective amount of a therapeutic preparation in the form of a dry powder containing (a) insulin and (b) an enhancer compound which enhances the absorption of insulin in the lungs of the patient.

The present invention relates to insulin and/or an insulin analogue conjugate, and a use thereof, wherein the insulin and/or insulin analogue have improved in vivo durability and stability by linking the same with an Fe region of immunoglobulin. The insulin and/or an insulin analogue conjugate of the present invention show an in vivo activity similar to that of insulin. In addition, the insulin and/or insulin analogue conjugate of the present invention are long-acting formulations of insulin and/or the analogue thereof, in which serum half-life is remarkably increased, and therefore, the present invention provides remarkable insulin and/or an insulin analogue conjugate, which do not induce hypoglycemia, a drawback of insulin treatment.

The optimal insulin to be delivered by an insulin infusion pump is determined by using a reinforcement learning algorithm aiming to the personalized glucose regulation. The algorithm optimizes the daily basal insulin rate and insulin: carbohydrate ratio for each patient, on the basis of his/her measured glucose profile. The proposed algorithm is able to learn in real-time patient-specific characteristics captured in the daily glucose profile and provide individualised insulin treatment. An automatic and personalised tuning method contributes in the optimisation of the algorithm's performance.

The invention relates to the field of biomedicine, in particular to a preparation method of a mesenchymal stem cell artificial pancreas islet. The preparation method of a mesenchymal stem cell artificial pancreas islet comprises the following steps of (1) culturing mesenchymal stem cells, and performing inducing to generate ancreas islet like cells; (2) performing extraction and culture of vascular endothelial cells; (3) preparing temperature-sensitive chitosan hydrogel; (4) preparing composite hydrogel; and (5) performing partial transplantation on the composite hydrogel obtained in the step(4), and rapidly performing agglutination under the 37 DEG C body temperature environment to form the artificial pancreas islet. According to the preparation method of the mesenchymal stem cell artificial pancreas islet disclosed by the invention, the problems of insulin resistance in the insulin treatment course, large number of pancreas islets required during pancreas islet transplantation and high immunological rejection reactions during pancreas islet transplantation are solved, and new donors are provided for pancreas islet transplantation for treating type I diabetes mellitus.

The invention discloses effect of long-chain inulin in adjusting acute pancreatitis and related tissue damage caused thereby, and belongs to the technical field of prevention and treatment of acute pancreatitis. It is verified herein that long-chain inulin can protect from caerulein-induced acute pancreatitis in mice and may be added, as an effective ingredient, to drugs for preventing and treating acute pancreatitis, thereby reducing occurrence and progress and degree of clinical acute pancreatitis. The long-chain inulin is used to carry out preventive treatment for a caerulein-induced mice acute pancreatitis model, pathomorphologic observation is carried out on pancreatic tissues of mice, the levels of serum pancrelipase, serum amylase and tissue inflammatory cell liberase in mice are measured, anti-inflammatory cytokine IL10 and pro-inflammatory cytokine TNF-Alpha and IL1 Beta in tissues and serum are also measured. By comparing index levels of mice in an insulin treatment group and an inflammatory model group, the indexes of mice in the inulin treatment group are significantly better those of the inflammatory model group.

The invention belongs to the field of medical technology and relates to a metformin hydrochloride chewable tablet and a preparation method thereof. The metformin hydrochloride chewable tablet is used for patients suffering from type-2 diabetes with pure unsatisfied diet control, in particular used for patients suffering from obesity and hyperinsulinemia, not only has the effect of reducing blood sugar level but also reducing body weight and alleviating hyperinsulinemia. The metformin hydrochloride chewable tablet is effective for some patients who are treated by sulfonylurea with poor curative effects, and has better effects in combination with sulfonylurea and small intestine glycosidase inhibitors or thiazolidinedione hypoglycemic drugs compared with single use. The metformin hydrochloride chewable tablet can be also used for patients with insulin treatment so as to reduce insulin dosage. The metformin hydrochloride chewable tablet is good in taste, simple and convenient in preparation process and easy to operate, especially suitable for children patients and fills up the blank of medication of children suffering from diabetes.

The present invention relates to GLP-1 receptor agonists for use in hypoglycaemia or hypoglycaemic episodes in patients treated with insulin and/or suffering from type 1 diabetes, e.g. for reducing the number of hypoglycaemia or hypoglycaemic episodes.

The invention discloses a wearable diabetes patient management system, and relates to the technical field of a diabetes patient monitoring management system, for solving the technical defect of lack of a scheme making and management system for conveniently and effectively injecting insulin into a diabetes patient in the prior art. The system comprises a patient wearable terminal and a medical care management end. The patient wearable terminal comprises a housing, and the housing is provided with an insulin storage groove; the housing is also provided with a microprocessing module and a communication module, a prompt module, an insulin detection module and a power supply module which are respectively connected with the microprocessing module; and the medical care management end is used for providing patient information management for medical care personnel, establishing communication connection with the patient wearable terminal, and making and remotely sending a prompt plan to the patient wearable terminal. The wearable diabetes patient management system can be used for carrying the insulin, can also give a timing prompt about injection to a patient, establishes the communication connection with the medical care management end, receives an injection scheme made by the medical care personnel through the medical care management end in a wireless mode, can also feed execution conditions timely to the medical care management end, realizes systemic management and monitoring and facilitates insensitive insulin treatment of the patient.

The invention belongs to the technical field of medicines and particularly relates to metformin hydrochloride dry suspension and a preparation method thereof. The metformin hydrochloride dry suspension is used for type-2 diabetes mellitus patients unsatisfied with pure diet control, particularly for obese patients accompanied by hyperinsulinemia, has the effect of reducing blood sugar and possibly has the effects of reducing weight and alleviating the hyperinsulinemia. The metformin hydrochloride dry suspension can take effect for certain patients with poor sulfonylurea curative effect. If the metformin hydrochloride dry suspension is used together with sulfonylurea, small intestine glycosidase inhibitors or thiazolidinediones hypoglycemic drugs, the effect is better than the effect achieved by single application. The metformin hydrochloride dry suspension can also be used for patients receiving insulin treatment so as to reduce the dosage of insulin. The metformin hydrochloride dry suspension has relatively good taste, is particularly suitable for child patients and fills in the blank of domestic child diabetes medication. The preparation technology of the metformin hydrochloride dry suspension is simple, convenient and practical.

The invention discloses an intelligent insulin injection device with a refrigeration function. The device aims at solving the technical problems that in the prior art, the temperature increasing timerequired by insulin taking from a refrigeration box causes maintenance of the high blood sugar concentration for a long time, and insulin with the corresponding treatment amount required by a patientcannot be injected. The intelligent insulin injection device comprises the refrigeration box, a refrigeration cavity is formed on the refrigeration box, and heat conduction blockage is arranged between the refrigeration cavity and the refrigeration box, and an insulin pump is arranged at one end of the refrigeration box; a preheating cavity is connected with the end of the refrigeration box, a first valve is arranged between the refrigeration box and the preheating cavity, and a piston is arranged in the preheating cavity; a liquid storage cavity is formed between the preheating cavity and theinsulin pump, a second valve is arranged at the bottom of the liquid storage cavity, the preheating cavity, the liquid storage cavity and the insulin pump are connected with conduits, and the first valve and the second valve are adjusted and controlled by a control module, and the control module analyzes the blood sugar concentration, detected by a detection module, of a user to obtain the insulin treatment amount required by the user, and the piston is adjusted, so that the insulin injection amount is the same as the insulin treatment amount.

Systems and methods are provided for adjusting a standing insulin medicament dosage regimen for a subject. Fasting events are identified using autonomous timestamped glucose measurements of the subject in a first data set. A second data set, from one or more insulin pens used to apply the standing regimen, comprises records, each record comprising a timestamped event specifying an amount of injected insulin medicament. Each fasting event is characterized as adherent or nonadherent. A fasting event is adherent when the second data set includes one or more records that temporally and quantitatively establish adherence with the standing regimen during the fasting event. Conversely, a fasting event is nonadherent when the second data set fails to temporally and quantitatively establish adherence with the standing regimen. Dosages in the standing regimen are adjusted using glucose measurements contemporaneous with adherent fasting events and by excluding glucose measurements contemporaneouswith nonadherent fasting events.

The invention provides a DNA nano machine. The DNA nano machine comprises a receptor and an actuator which are composed of nucleotide sequences, the receptor comprises a nucleotide chain R used for being combined with glucose molecules, and further comprises a nucleotide chain Hs and a closed chain Bs used for closing the Hs, the actuator comprises a nucleotide chain Ha and a closed chain Ba, the nucleotide chain Ha and the closed chain Ba are used for jointly acting with the Hs chain in the receptor to execute a certain function, the closed chain Ba is used for closing the Ha chain, and the Hs chain and the Ha chain can be subjected to partial chain segment base pairing, so that the Hs chain and the Ha chain can be combined to form a dimer structure, and the closed chain Bs chain and the closed chain Ba chain are correspondingly dissociated. The DNA nano machine responds to hyperglycemia in vivo and does not respond to low sugar, and has a hypoglycemic function only when the hyperglycemia in vivo exists, so that the risk of hypoglycemia in an insulin treatment process is avoided. The DNA nano machine has the advantages of intelligence, high efficiency, stability, low toxicity and the like.